Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab + Tuvonralimab with AI chemotherapy in first-line treatment of advanced UPS and DDLPS
ChiCTR2600129927Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Aug 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab, tuvonralimab, doxorubicin and ifosfamide in Malignant Fibrous Histiocytoma (MFH) and dedifferentiated liposarcoma (DDL), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Progression-Free Survival. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimabdoxorubicinifosfamide
03
Conditions
Malignant Fibrous Histiocytoma (MFH)dedifferentiated liposarcoma (DDL)
Beyond the preview
Go deeper on ChiCTR2600129927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129927.